» Articles » PMID: 32704299

HEP-Net Opinion on the Management of Ascites and Its Complications in the Setting of Decompensated Cirrhosis in the Resource Constrained Environment of Pakistan

Overview
Journal Pak J Med Sci
Specialty General Medicine
Date 2020 Jul 25
PMID 32704299
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Approximately one half of patients develop ascites within 10 years of diagnosis of compensated cirrhosis. It is a poor prognostic indicator, with only 50% surviving beyond two years. Mortality worsens significantly to 20% to 50% at one year if the ascites becomes refractory to medical therapy. Pakistan has one of the highest prevalence of viral hepatitis in the world and patients with ascites secondary to liver cirrhosis make a major percentage of both inpatient and outpatient burden. Studies indicate that over 80% of patients admitted with ascites have liver cirrhosis as the cause. This expert opinion suggests proper assessment of patients with ascites in the presence of underlying cirrhosis. This expert opinion includes appropriate diagnosis and management of uncomplicated ascites, refractory ascites and complicated ascites (including spontaneous bacterial peritonitis (SBP) ascites, hepatorenal syndrome (HRS) and hyponatremia. The purpose behind this expert opinion is to help consultants, postgraduate trainees, medical officers and primary care physicians optimally manage their patients with cirrhosis and ascites in a resource constrained setting as is often encountered in a developing country like Pakistan.

Citing Articles

Validation and exploratory factor analysis of Urdu Version of Chronic Liver Disease Questionnaire.

Hussain S, Zuberi B, Rasheed T, Ali F, Majid E Pak J Med Sci. 2023; 39(1):117-127.

PMID: 36694780 PMC: 9842985. DOI: 10.12669/pjms.39.1.6602.

References
1.
Kwok C, Krupa L, Mahtani A, Kaye D, Rushbrook S, Phillips M . Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int. 2013; 2013:295153. PMC: 3816020. DOI: 10.1155/2013/295153. View

2.
Wong R, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T . Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis. Liver Int. 2019; 39(6):1080-1088. DOI: 10.1111/liv.14040. View

3.
Llach J, Rimola A, Navasa M, Gines P, Salmeron J, Gines A . Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology. 1992; 16(3):724-7. DOI: 10.1002/hep.1840160318. View

4.
Majernikova M, Rosenberger J, Prihodova L, Jarcuskova M, Roland R, Groothoff J . Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients. Biomed Res Int. 2017; 2017:6987240. PMC: 5376439. DOI: 10.1155/2017/6987240. View

5.
Hiruy A, Nelson J, Zori A, Morelli G, Cabrera R, Kamel A . Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate. Eur J Gastroenterol Hepatol. 2020; 33(1):102-106. DOI: 10.1097/MEG.0000000000001700. View